Review article: Thiazolidinediones and heart failure
- PMID: 20368206
- DOI: 10.1177/1479164109338772
Review article: Thiazolidinediones and heart failure
Abstract
DM is an independent risk factor for the development of HF and its presence confers an adverse prognosis for those already diagnosed with HF.TZDs are potent insulin-sensitisers associated with a number of beneficial cardiovascular effects. However,TZDs increase renal sodium and water reabsorption, leading to fluid retention and overt signs of HF in patients with diabetes. Rosiglitazone has also been associated with an increased risk of myocardial infarction and cardiovascular mortality. However, pioglitazone may have macrovascular benefits. The majority of data on the cardiovascular safety of TZDs are based on non-cardovascular outcome trials and meta-analyses. Concerns regarding the risk of HF and cardiovascular safety of TZDs have led to restrictions on their use in patients with HF. This review addresses the latest evidence for HF with each of the TZD drugs currently available and reflects on the current guidelines regarding their prescription in at-risk patients.
Similar articles
-
Thiazolidinediones in type 2 diabetes: a cardiology perspective.Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Ann Pharmacother. 2008. PMID: 18698014 Review.
-
Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.Cerebrovasc Dis. 2013;36(2):145-51. doi: 10.1159/000353679. Epub 2013 Sep 11. Cerebrovasc Dis. 2013. PMID: 24029780
-
Effects of the thiazolidinedione medications on micro- and macrovascular complications in patients with diabetes--update 2008.Cardiovasc Drugs Ther. 2008 Jun;22(3):233-40. doi: 10.1007/s10557-008-6093-z. Epub 2008 Mar 29. Cardiovasc Drugs Ther. 2008. PMID: 18373186 Review.
-
Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.Clin Ther. 2011 Dec;33(12):1904-13. doi: 10.1016/j.clinthera.2011.10.025. Epub 2011 Nov 25. Clin Ther. 2011. PMID: 22118894
-
Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?Diab Vasc Dis Res. 2005 May;2(2):61-6. doi: 10.3132/dvdr.2005.010. Diab Vasc Dis Res. 2005. PMID: 16305060 Review.
Cited by
-
Blood pressure and cardiovascular effects of new and emerging antidiabetic agents.Curr Hypertens Rep. 2014 Aug;16(8):455. doi: 10.1007/s11906-014-0455-7. Curr Hypertens Rep. 2014. PMID: 24908134 Free PMC article. Review.
-
Optimal glycaemic control in elderly people with type 2 diabetes: what does the evidence say?Drug Saf. 2015 Jan;38(1):17-32. doi: 10.1007/s40264-014-0247-7. Drug Saf. 2015. PMID: 25481812 Review.
-
Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study.J Diabetes Res. 2015;2015:834903. doi: 10.1155/2015/834903. Epub 2015 Apr 28. J Diabetes Res. 2015. PMID: 26060825 Free PMC article.
-
Examining the Potential of Developing and Implementing Use of Adiponectin-_targeted Therapeutics for Metabolic and Cardiovascular Diseases.Front Endocrinol (Lausanne). 2019 Dec 11;10:842. doi: 10.3389/fendo.2019.00842. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31920962 Free PMC article. Review.
-
Adiponectin retards the progression of diabetic nephropathy in db/db mice by counteracting angiotensin II.Physiol Rep. 2014 Feb 10;2(2):e00230. doi: 10.1002/phy2.230. eCollection 2014 Feb 1. Physiol Rep. 2014. PMID: 24744899 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous